康臣药业获纳入恒生综合指数 有望成为港股通标的

Core Viewpoint - Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series as of December 31, 2025, with Kang Hsin Pharmaceutical (01681) being included in the Hang Seng Composite Index, effective after market close on March 6, 2026, and effective from March 9, 2026 [1] Group 1 - The inclusion of Kang Hsin Pharmaceutical in the Hang Seng Composite Index will lead to adjustments in the investable universe of Hong Kong Stock Connect by the Shanghai and Shenzhen Stock Exchanges [1] - According to a report by CICC, Kang Hsin Pharmaceutical is likely to be included in the Hong Kong Stock Connect due to meeting various criteria, including market capitalization, liquidity, and listing duration [1] Group 2 - Kang Hsin Pharmaceutical previously announced on June 13, 2025, that its board of directors resolved to execute a share buyback plan with a total fund not exceeding HKD 200 million for repurchasing shares in the open market [1] - On January 29, 2026, the board further resolved to execute an additional share buyback plan with a maximum additional fund of HKD 100 million, bringing the total planned expenditure for share buybacks to not exceed HKD 300 million [1] - The duration of the share buyback plan will last from the date of the announcement until the conclusion of the next annual general meeting or until the shareholders withdraw or amend the buyback authorization at the general meeting [1]